A meta-analysis of 13 RCTs demonstrated that short-acting insulin analogues provide better control of HbA1c and postprandial glucose in T2DM than regular human insulin, with no substantial reduction in the risk of severe hypoglycemia [37]. This evidence concerns the gene INS and Hypoglycemia.